Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441109 · ClinicalTrials.gov registry record · NA
Shatavari Root Extract for Perimenopausal Symptoms
A NA study, sponsored by SF Research Institute.
- Not yet
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT07441109 is a NA study that has not yet begun recruiting, run by SF Research Institute. The registered enrollment target is 60 participants.
The verdict
NCT07441109, a NA study, has not yet begun recruiting, sponsored by SF Research Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. Efficacy will be assessed using validated menopause-specific symptom, quality-of-life, stress, mood, and sleep questionnaires, along with physiological stress markers. Safety will be evaluated through laboratory assessments and adverse event monitoring.
Interventions
- OTHER Placebo Capsule
- DIETARY_SUPPLEMENT Shatavari (Asparagus racemosus) Root Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2026-06-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441109
The ClinicalTrials.gov registry entry for NCT07441109 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SF Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Capsule is the first listed.
NCT07441109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07441109 about?
NCT07441109 is a clinical study titled "Shatavari Root Extract for Perimenopausal Symptoms". This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. ...
What is the current status of trial NCT07441109?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-03-11. Estimated completion is 2026-06-29.
What interventions are being tested in trial NCT07441109?
The interventions under investigation include: Placebo Capsule (OTHER), Shatavari (Asparagus racemosus) Root Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07441109?
This trial is sponsored by SF Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.